Second Successful Phase I/II Clinical Trial For BiondVax’s Universal Flu Vaccine
Friday, April 30th, 2010We recommend: without prescription accutane, without prescription lexapro, without prescription rimonabant
Main Category: Infectious Diseases / Bacteria / Viruses
Also Included In: Swine Flu ; Flu / Cold / SARS ; Immune System / Vaccines
netmail to a protagonist pressman well-disposed horizon / publish opinions
BiondVax Pharmaceuticals Ltd. (TASE:BNDK), an Israeli biopharmaceutical fellowship at the vanguard of world efforts towards the ontogenesis of a Universal Influenza Vaccine, proclaimed the successful decision of the Company’s secondment Phase I/II clinical tryout of the Multimeric-001 Universal Influenza Vaccine. This secondment Phase I/II tryout was a randomised, single-blind, placebo-controlled, escalating double-dose refuge discipline conducted at the Sourasky Medical Center in Tel Aviv, Israel, in which a add of 60 participants, males and females ripened 55-75, standard two intramuscular injections containing the vaccinum, either with or without accessory, and at two dissimilar superman levels. This was so followed by an brass of a commercially usable seasonal grippe vaccinum.
